Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016-Reference-Cited by-同舟云学术

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pfaller Michael A.¹²,Flamm Robert K.¹,Mendes Rodrigo E.¹,Streit Jennifer M.¹,Smart Jennifer I.³,Hamed Kamal A.³^ORCID,Duncan Leonard R.¹,Sader Helio S.¹

Affiliation:

1. JMI Laboratories, North Liberty, Iowa, USA

2. University of Iowa, Iowa City, Iowa, USA

3. Basilea Pharmaceutica International Ltd., Basel, Switzerland

Abstract

Ceftobiprole is an advanced cephalosporin with potent activity against Gram-positive and Gram-negative bacteria that has been approved in many European and non-European countries to treat community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia). This study reports on the activity of ceftobiprole against a large set of clinical isolates obtained from hospitalized patients in the United States in 2016 that caused serious infections, including pneumonia, bacteremia, and skin and skin structure infections.

Funder

HHS | Biomedical Advanced Research and Development Authority

Basilea Pharmaceutica

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01566-18

Reference24 articles.

1. Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010

2. Antimicrobial activity of ceftobiprole, a novel anti–methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)